Patients who especially stand to benefit from our findings include those who do not have to access to newer therapies such as anlotinib and cancer vaccines or are ineligible for adoptive immunotherapy due to absence of the HLA-A*02:01 allele. This evidence concerns the gene HLA-A and cancer.